Polybacterial human disease: The ills of social networking

Trends in Microbiology

Volumn 22, Issue 9, 2014, Pages 508-516

  Short, Francesca L ^a   Murdoch, Sarah L ^a   Ryan, Robert P ^a  

^a UNIVERSITY OF DUNDEE   (United Kingdom)

Author keywords

Cell cell signaling; Infection; Metatranscriptomics; Polybacterial disease; Polymicrobial infection; Synergy

Indexed keywords

AUTOINDUCER 2; DIFFUSIBLE SIGNAL FACTOR; FATTY ACID; INDOLE; RIBOSE; UNCLASSIFIED DRUG; ANTIINFECTIVE AGENT;

ANTIBIOTIC BIOSYNTHESIS; BACTERIAL INFECTION; BACTERIAL METABOLISM; BACTERIUM ADHERENCE; BIOFILM; COMPETITIVE ABILITY; HUMAN; INFECTION CONTROL; INTERSPECIFIC RELATIONSHIP; MICROBIAL COMMUNITY; MIXED INFECTION; NONHUMAN; ORGANISMAL INTERACTION; PRIORITY JOURNAL; QUORUM SENSING; REVIEW; SIGNAL TRANSDUCTION; TREATMENT PLANNING; BACTERIAL INFECTIONS; BACTERIUM; BIOLOGICAL MODEL; DRUG EFFECTS; METABOLISM; MICROBIOLOGY; PATHOGENICITY; VIRULENCE;

BACTERIA (MICROORGANISMS);

ANTI-BACTERIAL AGENTS; BACTERIA; BACTERIAL INFECTIONS; HUMANS; MICROBIAL INTERACTIONS; MODELS, BIOLOGICAL; SIGNAL TRANSDUCTION; VIRULENCE;

EID: 84906937658     PISSN: 0966842X     EISSN: 18784380     Source Type: Journal    
DOI: 10.1016/j.tim.2014.05.007     Document Type: Review

References (89)

1. Peters B.M., et al. Polymicrobial interactions: impact on pathogenesis and human disease. Clin. Microbiol. Rev. 2012, 25:193-213.
2. Brogden K.A., et al. Human polymicrobial infections. Lancet 2004, 365:253-255.
3. McCullers J.A. The co-pathogenesis of influenza viruses with bacteria in the lung. Nat. Rev. Microbiol. 2014, 12:252-262.
4. Harriott M.M., Noverr M.C. Importance of Candida-bacterial polymicrobial biofilms in disease. Trends Microbiol. 2011, 19:557-563.
5. Riedel K., et al. N-acylhomoserine-lactone-mediated communication between Pseudomonas aeruginosa and Burkholderia cepacia in mixed biofilms. Microbiology 2001, 147:3249-3262.
6. Fugère A., et al. Interspecific small molecule interactions between clinical isolates of Pseudomonas aeruginosa and Staphylococcus aureus from adult cystic fibrosis patients. PLoS ONE 2014, 9:e86705.
7. Hardie K.R., Heurlier K. Establishing bacterial communities by "word of mouth": LuxS and autoinducer 2 in biofilm development. Nat. Rev. Microbiol. 2008, 6:635-643.
8. Pereira C.S., et al. AI-2-mediated signalling in bacteria. FEMS Microbiol. Rev. 2013, 37:156-181.
9. Armbruster C., et al. Indirect pathogenicity of Haemophilus influenzae and Moraxella catarrhalis in polymicrobial otitis media occurs via interspecies quorum signaling. MBio 2010, 10.1128/mBio.00102-10.
10. Perez A.C., et al. Residence of Streptococcus pneumoniae and Moraxella catarrhalis within polymicrobial biofilm promotes antibiotic resistance and bacterial persistence in vivo. Pathog. Dis. 2014, 70:280-288.
11. Duan K., et al. Modulation of Pseudomonas aeruginosa gene expression by host microflora through interspecies communication. Mol. Microbiol. 2003, 50:1477-1491.
12. Ryan R.P., Dow J.M. Communication with a growing family: diffusible signal factor (DSF) signaling in bacteria. Trends Microbiol. 2011, 19:145-152.
13. Ryan R.P., et al. Interspecies signalling via the Stenotrophomonas maltophilia diffusible signal factor influences biofilm formation and polymyxin tolerance in Pseudomonas aeruginosa. Mol. Microbiol. 2008, 68:75-86.
14. Deng Y., et al. Cis-2-dodecenoic acid signal modulates virulence of Pseudomonas aeruginosa through interference with quorum sensing systems and T3SS. BMC Microbiol. 2013, 13:231-242.
15. Twomey K.B., et al. Bacterial cis-2-unsaturated fatty acids found in the cystic fibrosis airway modulate virulence and persistence of Pseudomonas aeruginosa. ISME J. 2012, 6:939-950.
16. Bernier S.P., Surette M.G. Concentration-dependent activity of antibiotics in natural environments. Front. Microbiol. 2013, 4:20.
17. Kaplan J., et al. Low levels of β-lactam antibiotics induce extracellular DNA release and biofilm formation in Staphylococcus aureus. MBio 2012, 3:e00198-e212.
18. Lee J., Lee J. Indole as an intercellular signal in microbial communities. FEMS Microbiol. Rev. 2010, 34:426-444.
19. Chu W., et al. Indole production promotes Escherichia coli mixed-culture growth with Pseudomonas aeruginosa by inhibiting quorum signaling. Appl. Environ. Microbiol. 2012, 78:411-419.
20. Lee J., et al. Indole and 7-benzyloxyindole attenuate the virulence of Staphylococcus aureus. Appl. Microbiol. Biotechnol. 2013, 97:4543-4552.
21. Korgaonkar A., et al. Community surveillance enhances Pseudomonas aeruginosa virulence during polymicrobial infection. Proc. Natl. Acad. Sci. U.S.A. 2013, 110:1059-1064.
22. Ramsey M.M., Whiteley M. Polymicrobial interactions stimulate resistance to host innate immunity through metabolite perception. Proc. Natl. Acad. Sci. U.S.A. 2009, 106:1578-1583.
23. Wickström C., et al. Proteolytic degradation of human salivary MUC5B by dental biofilms. Microbiology 2009, 155:2866-2872.
24. Wickström C., Svensäter G. Salivary gel-forming mucin MUC5B - a nutrient for dental plaque bacteria. Oral Microbiol. Immunol. 2008, 23:177-182.
25. Egland P.G., et al. Interspecies communication in Streptococcus gordonii-Veillonella atypica biofilms: signaling in flow conditions requires juxtaposition. Proc. Natl. Acad. Sci. U.S.A. 2004, 101:16917-16922.
26. Ramsey M.M., et al. Metabolite cross-feeding enhances virulence in a model polymicrobial infection. PLoS Pathog. 2011, 7:e1002012.
27. Venkataraman A., Rosenbaum M. Metabolite transfer with the fermentation product 2,3-butanediol enhances virulence by Pseudomonas aeruginosa. ISME J. 2014, 8:1210-1220.
28. Lee K.W.K., et al. Biofilm development and enhanced stress resistance of a model, mixed-species community biofilm. ISME J. 2014, 8:894-907.
29. Bragonzi A., et al. Modelling co-infection of the cystic fibrosis lung by Pseudomonas aeruginosa and Burkholderia cenocepacia reveals influences on biofilm formation and host response. PLoS ONE 2012, 7:e52330.
30. Barken K.B., et al. Roles of type IV pili, flagellum-mediated motility and extracellular DNA in the formation of mature multicellular structures in Pseudomonas aeruginosa biofilms. Environ. Microbiol. 2008, 10:2331-2343.
31. Pratt L.A., Kolter R. Genetic analysis of Escherichia coli biofilm formation: roles of flagella, motility, chemotaxis and type I pili. Mol. Microbiol. 1998, 30:285-293.
32. O'Toole G.A., Kolter R. Flagellar and twitching motility are necessary for Pseudomonas aeruginosa biofilm development. Mol. Microbiol. 1998, 30:295-304.
33. Watnick P.I., Kolter R. Steps in the development of a Vibrio cholerae El Tor biofilm. Mol. Microbiol. 1999, 34:586-595.
34. Wright C.J., et al. Microbial interactions in building of communities. Mol. Oral Microbiol. 2013, 28:83-101.
35. Huang R., et al. Bacterial interactions in dental biofilm. Virulence 2011, 2:435-444.
36. Pereira A.L., et al. Diarrhea-associated biofilm formed by enteroaggregative Escherichia coli and aggregative Citrobacter freundii: a consortium mediated by putative F pili. BMC Microbiol. 2010, 10:57.
37. Edwards A.M., et al. Fusobacterium nucleatum transports noninvasive Streptococcus cristatus into human epithelial cells. Infect. Immun. 2006, 74:654-662.
38. Cope E.K., et al. Regulation of virulence gene expression resulting from Streptococcus pneumoniae and nontypeable Haemophilus influenzae interactions in chronic disease. PLoS ONE 2011, 6:e28523.
39. Pukatzki S., et al. Identification of a conserved bacterial protein secretion system in Vibrio cholerae using the Dictyostelium host model system. Proc. Natl. Acad. Sci. U.S.A. 2006, 103:1528-1533.
40. Mougous J.D., et al. A virulence locus of Pseudomonas aeruginosa encodes a protein secretion apparatus. Science 2006, 312:1526-1530.
41. Russell A.B., et al. Type VI secretion system effectors: poisons with a purpose. Nat. Rev. Microbiol. 2014, 12:137-148.
42. Schwarz S., et al. Burkholderia type VI secretion systems have distinct roles in eukaryotic and bacterial cell interactions. PLoS Pathog. 2010, 6:e1001068.
43. Murdoch S.L., et al. The opportunistic pathogen Serratia marcescens utilizes type VI secretion to target bacterial competitors. J. Bacteriol. 2011, 193:6057-6069.
44. Malvankar N.S., Lovley D.R. Microbial nanowires: a new paradigm for biological electron transfer and bioelectronics. ChemSusChem 2012, 5:1039-1046.
45. Ruhe Z.C., et al. Bacterial contact-dependent growth inhibition. Trends Microbiol. 2013, 21:230-237.
46. Lim Y.W., et al. Metagenomics and metatranscriptomics: windows on CF-associated viral and microbial communities. J. Cyst. Fibros. 2012, 12:154-164.
47. Twomey K.B., et al. Microbiota and metabolite profiling reveal specific alterations in bacterial community structure and environment in the cystic fibrosis airway during exacerbation. PLoS ONE 2013, 8:e82432.
48. Moree W.J., et al. Interkingdom metabolic transformations captured by microbial imaging mass spectrometry. Proc. Natl. Acad. Sci. U.S.A. 2012, 109:13811-13816.
49. Jorth P., et al. Probing bacterial metabolism during infection using high-resolution transcriptomics. J. Bacteriol. 2013, 195:4991-4998.
50. Talbot G.H., et al. Bad bugs need drugs: an update on the development pipeline from the Antimicrobial Availability Task Force of the Infectious Diseases Society of America. Clin. Infect. Dis. 2006, 42:657-668.
51. Lewis K. Platforms for antibiotic discovery. Nat. Rev. Drug Discov. 2013, 12:371-387.
52. Bjarnsholt T., et al. Applying insights from biofilm biology to drug development - can a new approach be developed?. Nat. Rev. Drug Discov. 2013, 12:791-808.
53. Kostakioti M. Bacterial biofilms: development, dispersal, and therapeutic strategies in the dawn of the postantibiotic era. Cold Spring Harb. Perspect. Med. 2013, 3. 10.1101/cshperspect.a010306.
54. Leekha S., et al. General principles of antimicrobial therapy. Mayo Clin. Proc. 1991, 86:156-167.
55. Njoroge J., Sperandio V. Jamming bacterial communication: new approaches for the treatment of infectious diseases. EMBO Mol. Med. 2009, 1:201-210.
56. Rasko D., Sperandio V. Anti-virulence strategies to combat bacteria-mediated disease. Nat. Rev. Drug Discov. 2010, 9:117-128.
57. Deng Y., et al. Diffusible signal factor (DSF) quorum sensing signal and structurally related molecules enhance the antimicrobial efficacy of antibiotics against some bacterial pathogens. BMC Microbiol. 2014, 14:51.
58. Lee J., et al. Indole and 7-hydroxyindole diminish Pseudomonas aeruginosa virulence. Microb. Biotechnol. 2009, 2:75-90.
59. Chorell E., Pinkner J. Design and synthesis of C-2 substituted thiazolo and dihydrothiazolo ring-fused 2-pyridones: pilicides with increased antivirulence activity. J. Med. Chem. 2010, 53:5690-5695.
60. Chorell E., et al. Synthesis and application of a bromomethyl substituted scaffold to be used for efficient optimization of anti-virulence activity. Eur. J. Med. Chem. 2011, 46:1103-1116.
61. Hartmann M., et al. Inhibition of bacterial adhesion to live human cells: activity and cytotoxicity of synthetic mannosides. FEBS Lett. 2012, 586:1459-1465.
62. Baldan R., et al. Adaptation of Pseudomonas aeruginosa in cystic fibrosis airways influences virulence of Staphylococcus aureus in vitro and murine models of co-infection. PLoS ONE 2014, 9:e89614.
63. O'Sullivan A.K., et al. Health care utilization and costs for cystic fibrosis patients with pulmonary infections. Manag. Care 2011, 20:37-44.
64. Armbruster C.E., et al. Increased incidence of urolithiasis and bacteremia during Proteus mirabilis and Providencia stuartii coinfection due to synergistic induction of urease activity. J. Infect. Dis. 2014, 209:1524-1532.
65. Von Eiff C., et al. Infections associated with medical devices: pathogenesis, management and prophylaxis. Drugs 2005, 65:179-214.
66. Kline K.A., et al. Immune modulation by group B Streptococcus influences host susceptibility to urinary tract infection by uropathogenic Escherichia coli. Infect. Immun. 2012, 80:4186-4194.
67. Foxman B. Epidemiology of urinary tract infections: incidence, morbidity, and economic costs. Dis. Mon. 2003, 49:53-70.
68. Thomas C.P., et al. Incidence and cost of pneumonia in medicare beneficiaries. Chest 2012, 142:973-981.
69. Shak J.R., et al. Influence of bacterial interactions on pneumococcal colonization of the nasopharynx. Trends Microbiol. 2013, 21:129-135.
70. Ahmed S., et al. Incremental health care utilization and costs for acute otitis media in children. Laryngoscope 2014, 124:301-305.
71. Grenier D., Mayrand D. Nutritional relationships between oral bacteria. Infect. Immun. 1986, 53:616-620.
72. Grenier D. Nutritional interactions between two suspected periodontopathogens, Treponema denticola and Porphyromonas gingivalis. Infect. Immun. 1992, 60:5298-5301.
73. Chapple I.L.C. Time to take periodontitis seriously. BMJ 2014, 348. 10.1136/bmj.g2645.
74. Karchmer A.W. Microbiology and treatment of diabetic foot infections. The Diabetic Foot: Medical and Surgical Management 2012, 331-346. Humana Press. A. Veves (Ed.).
75. Pastar I., et al. Interactions of methicillin resistant Staphylococcus aureus USA300 and Pseudomonas aeruginosa in polymicrobial wound infection. PLoS ONE 2013, 8:e56846.
76. Rice J.B., et al. Burden of diabetic foot ulcers for medicare and private insurers. Diabetes Care 2014, 37:651-658.
77. Dowd S.E., et al. Polymicrobial nature of chronic diabetic foot ulcer biofilm infections determined using bacterial tag encoded FLX amplicon pyrosequencing (bTEFAP). PLoS ONE 2008, 3:e3326.
78. Higgins P., Johnson L. Prior Helicobacter pylori infection ameliorates Salmonella Typhimurium-induced colitis: mucosal crosstalk between stomach and distal intestine. Inflamm. Bowel Dis. 2011, 17:1398-1408.
79. Kostic A.D., et al. The microbiome in inflammatory bowel disease: current status and the future ahead. Gastroenterology 2014, 146:1489-1499.
80. Sibley C.D., et al. Discerning the complexity of community interactions using a Drosophila model of polymicrobial infections. PLoS Pathog. 2008, 4:e1000184.
81. Kesavalu L., et al. Rat model of polymicrobial infection, immunity, and alveolar bone resorption in periodontal disease. Infect. Immun. 2007, 75:1704-1712.
82. Wilke M., et al. Mouse models of cystic fibrosis: phenotypic analysis and research applications. J. Cyst. Fibros. 2011, 10(Suppl. 2):S152-S171.
83. Keiser N., Engelhardt J. New animal models of cystic fibrosis: what are they teaching us?. Curr. Opin. Pulm. Med. 2011, 17:478-483.
84. Febrer M., et al. Advances in bacterial transcriptome and transposon insertion-site profiling using second-generation sequencing. Trends Biotechnol. 2011, 29:586-594.
85. Surette M.G. The cystic fibrosis lung microbiome. Ann. Am. Thorac. Soc. 2014, 11(Suppl. 1):S61-S65.
86. Rogers G.B., et al. Interpreting infective microbiota: the importance of an ecological perspective. Trends Microbiol. 2013, 21:271-276.
87. Pattison S.H., et al. Molecular detection of CF lung pathogens: current status and future potential. J. Cyst. Fibros. 2013, 12:194-205.
88. Sibley C.D., Surette M.G. The polymicrobial nature of airway infections in cystic fibrosis: Cangene Gold Medal Lecture. Can. J. Microbiol. 2011, 57:69-77.
89. Willner D., et al. Spatial distribution of microbial communities in the cystic fibrosis lung. ISME J. 2012, 6:471-474.